Wednesday, March 9, 2016

Stimulant Medications for treating ADHD: A comparison

ADHD medication is a big business in the world today.  Annual sales of ADHD medication are projected to be 15-20 billion dollars by 2020, increasing at a rate of about 8% per year.   To put this in perspective, this is similar to the value of the worldwide market for fresh vegetables
 ( http://siteresources.worldbank.org/INTPROSPECTS/Resources/GATChapter13.pdf ).

 It is an amount of money that would pay for the salaries of
 400 000 teachers, each of whom paid $50 000 per year. 

 A relevant article to look at about this is by Alan Schwartz, published in the New York Times in 2013:
http://www.nytimes.com/2013/12/15/health/the-selling-of-attention-deficit-disorder.html?pagewanted=all&_r=0

I am not meaning this post to be a discussion of the controversies of ADHD diagnosis.  Instead, this post will focus mainly about ADHD medication.   I think the rising rate of ADHD diagnosis, and the rising rate of stimulant prescription,  is a very concerning trend, particularly if these diagnoses and treatments are offered without attending adequately to other biopsychosocial factors, and particularly if these treatments are being offered under the influence of un-recognized biases due to the financial power and influence of the manufacturers.

On the other hand, the rising awareness and acceptance of ADHD can allow those children, adults, and families who are dealing with ADHD-related issues to feel less stigmatized, judged, and unfairly treated.  In families, knowledge and acceptance of ADHD can help child-rearing practices to be adapted, so as to avoid a harshly punitive stance towards those children with attention problems.  


The newer ADHD medications are, not surprisingly, very popular, frequently prescribed, are often touted as being better than the older medications, and are listed first on medication advice guideline sheets (such as the CADDRA recommendations).

Here is a comparison of costs per day between the different ADHD drugs, looking at a typical full therapeutic dose for an adult.  These cost estimates come from a site called "Pharmacy Compass" which searches for the best local prices for medications at pharmacies.   

1. Newer drugs (CADDRA considers these to be the only "first line" medications):

Adderall XR 30 mg:$3.91 per day
Biphentin 80 mg:$4.36 per day
Concerta 72 mg:$5.92 per day
Vyvanse 60 mg:  $5.14 per day
Strattera 100 mg: $5.51 per day


2. Older drugs (CADDRA considers these "second line"):

Dexedrine spansules 40 mg: $3.59 per day

Ritalin (methylphenidate) 60 mg: $0.81 per day
 Ritalin SR 60 mg $0.66 per day


So we see that the least expensive option is methylphenidate or methylphenidate SR.  Dexedrine is over 5 times as expensive.  Concerta and Vyvanse are about 8 times as expensive, per day.

I mention these expense differences not necessarily in an effort to favour the cheaper medication, but rather to heighten your anticipation that there could be bias in any research results regarding these medications--especially if the research is sponsored by the manufacturers-- due to the huge profit motives involved.


It would be fair to look for studies which carefully and prospectively treat ADHD patients with Ritalin vs. one of the newer medications, in randomized comparisons.

1) Vyvanse vs. Ritalin.  Almost no studies in the literature!  In one study, all they looked at was whether patients stuck to a dosing regimen, in which case the Vyvanse group did "better." (http://www.ncbi.nlm.nih.gov/pubmed/23937642 ) But this measure had nothing to do with the patients actually feeling better or improving more!

A better study compared Vyvanse with Oros-MPH, a long-acting version of Ritalin (though not plain old Ritalin itself!)
[ http://www.ncbi.nlm.nih.gov/pubmed/23801529]

In this study, at first glance it certainly appears that Vyvanse is better!  But looking carefully, one finds statements such as this: "At endpoint, the difference between lisdexamfetamine and OROS-MPH in the percentage of patients with an ADHD-RS-IV total score less than or equal to the mean for their age was not statistically significant." (p.747)   This statement was tucked into the results section but left out of the conclusion.  Looking at side-effects, we find a lower total rate of adverse effects in the Ritalin group.  Reduced appetite, insomnia, and nausea were more common in the Vyvanse group.  Notably, there is a long list of conflicts of interest at the end of this paper, including some of the authors being employees of the Vyvanse manufacturer, and owning stocks in the company!


In conclusion here, there is no doubt that Vyvanse is an effective medication for ADHD.  The dosing regime is very convenient, which may be particularly effective and helpful for many.  But it is not necessarily superior to much cheaper alternatives.  For some people (including many patients I have seen), regular methylphenidate (Ritalin) allows better fine control of symptoms during the course of the day, without being "stuck" with a continuous sustained-release effect.  For others, they certainly do prefer the Vyvanse.  I just think that Vyvanse should not be assumed to be better, as the evidence is very weak that it is, while it is 8 times more expensive than Ritalin!

2) Concerta vs. Ritalin
http://www.ncbi.nlm.nih.gov/pubmed/11389303
This is a good early study, directly comparing the two medications, published in Pediatrics in 2001.  Here is the authors' concise summary: "On virtually all measures in all settings, both drug conditions were significantly different from placebo, and the 2 drugs were not different from each other."   The reason to choose Concerta over Ritalin would be convenience.  The authors do point out that "compliance" is more likely on a long-acting formulation.  But remember that "compliance" is a very, very indirect, and possibly irrelevant, measure of health and well-being!!  Why is it important that there be better "compliance?"   Should the only criteria not be well-being?   Certainly this is not a reason to classify Concerta as "better" or "first line".  Concerta is 9 times more expensive than Ritalin!

3) Adderall vs Ritalin
http://www.ncbi.nlm.nih.gov/pubmed/10103335
In this study, published in Pediatrics in 1999, Adderall comes out as looking better than Ritalin.  But, once again, the study was sponsored by the manufacturer.  On a close look, a couple of problems:  first, the doses of the medications were fixed.  The ritalin doses appear too low, so as not to match the equivalent doses of Adderall given.  At this point, one would usually give Ritalin doses at least twice that of Adderall (i.e. 100% higher) but in this study the Ritalin dose was only 40% higher than the Adderall dose.  In accordance with this under-dosing, the Adderall group not surprisingly had more side effects such as insomnia.

In conclusion, there is no doubt that Adderall XR is a good medication for ADHD.  Many of my patients have preferred it over other alternatives.  But it is not fair, once again, to assume that it is better.  It does not deserve to be considered "first line" while a similarly-effective alternative that is one-sixth the cost is considered "second line."

4) Meta-analytic comparison:
Faraone and Glatt (2010) have published a good meta-analytic review paper, which is worth reading in detail, with particular attention to the data tables and graphs:   http://www.ncbi.nlm.nih.gov/pubmed/20051220
In the conclusion of this paper, the authors state that they "found no significant differences between short- and long-acting stimulant medications."

Addendum:  a recent Cochrane review, published in February 2016 by Punja et al., concludes that there is a lot of evidence that amphetamines reduce core symptoms of ADHD, but cause a variety of problematic side-effects.  They note that there was evidence of a lot of bias in the studies they looked at, with the quality of evidence being low to very low.

Here is a direct quote from their conclusion:   "This review found no evidence that supports any one amphetamine derivative over another, and does not reveal any differences between long-acting and short-acting amphetamine preparations." 



Friday, February 19, 2016

Do Higher Doses of Antidepressants Work Better?

It is common practice in psychiatry to increase the dose of an antidepressant if the standard dose is not helping enough.  Sometimes doses are increased before even finding out if the lower dose is working. 

But it is interesting to consider evidence that higher doses actually do not necessarily work better:

RuhĂ© et al. (2009-2010) have published research on this issue, and conclude that SSRI dose increases do not improve effectiveness.  Their explanation for this is quite simple:  serotonin receptors are already well-occupied at standard doses, and this does not change with dose increases:  
http://www.ncbi.nlm.nih.gov/pubmed/18830236
http://www.ncbi.nlm.nih.gov/pubmed/20862644

In general, it is indeed interesting to see scanty evidence that increasing antidepressant doses lead to improved effectiveness, even for treatment-resistant cases.  

This issue came to my attention upon reading Lam's recent article about using light therapy to treat non-seasonal depression   ( http://www.ncbi.nlm.nih.gov/pubmed/26580307).  Their medication groups used only 20 mg of fluoxetine, without the possibility of increasing the dose.  They cited some old, dated references to support this, such as Altamura et al (1988), and  Beasley (1990):
http://www.ncbi.nlm.nih.gov/pubmed/2196623 
 
A better, more recent article reviewing antidepressant dose vs effectiveness is by Berney (2006):
http://www.ncbi.nlm.nih.gov/pubmed/16156383


In many studies, higher doses may appear to work better, mainly because the dose was increased before the lower dose had a chance to work fully.   The lower dose may well have worked just as well as the higher dose.  Controlled studies comparing different doses do not support the belief that higher doses work better.

So it should not be routine practice to increase antidepressant doses beyond a standard "full dose" which is usually one tablet or capsule daily.    In many cases, the different dosage regimes are likely to be equivalent.  It is relevant to consider that higher doses mainly benefit the pharmaceutical companies, since they are selling more product despite the effectiveness being the same.  Therefore, presentations of research data about antidepressant effectiveness may be biased in favour of higher doses.  An extremely common research design in antidepressant studies is to have "flexible dosing," usually leading to the antidepressant group averaging about twice the standard dose in the end.  This design, even when treatment effects are shown, biases the reader to have the specious conclusion that higher doses are better.

However, there are certainly many individual case reports of higher doses being more useful.  So dose increases may have a role in some cases.

The key point is to question dose increases as a reflexive, routine management strategy for inadequate antidepressant effects.  Alternative strategies include giving the lower dose a longer try, switching to something else, or using some form of augmentation.

Addendum:

Just days after posting this, I see there is a new meta-analysis by Jakubovski et al. in The American Journal of Psychiatry (173:2,pp. 174-183) which suggests that SSRI antidepressants do actually work slightly better at higher doses, peaking at 2.5 times the standard dose (e.g. 50 mg fluoxetine).   They admit that the data show a trade-off between slight improved effectiveness at higher doses, but accompanied by worsened tolerability. 

Yet, it is important to consider that higher doses could reflect a greater placebo effect; some of the research about active placebos show that agents which cause more side effects are likely to have a larger impact on symptoms than inert placebos.  Because antidepressants at higher doses have more side effects, there would be more of this "active placebo" effect.  See my previous post on this subject: http://garthkroeker.blogspot.ca/2009/03/active-placebos.html


It's hard to know what to make of this, other than to probably remain open-minded about the issue.  I think that a better study design for this type of issue is to look at dose comparisons within individual clinical trials, rather than to amass data meta-analytically.   Active placebo comparison groups would also be useful.  For example, agents which would cause very mild side-effects could be used instead of a totally inert placebo, so as to improve the blinding of the studies.    In many individual clinical trials of antidepressants (both new and old) which compare doses or dose ranges within the studies themselves, there are no significant differences in effectiveness.

Another issue, which the authors point out, is that most antidepressant studies have strict inclusion criteria which usually do not match the type of cases one would tend to see clinically most often.  Many studies require a major depressive disorder diagnosis, with limited comorbidities allowed, and with limited past treatment trials, etc.

Meanwhile, it remains reasonable to give a baseline dose of antidepressants an adequate length of time to work, without reflexively increasing the dose on a routine basis.   Dose increases remain an option, with some evidence-based support, but switching or augmentation could often be preferred, depending on patient preference and side-effects. 

Thursday, February 18, 2016

Mental Health Care Organization & Advocacy


A grave problem in the world today is the lack of timely access to mental health care.

The roots of this problem are located in basic societal factors, such as poverty, political oppression, crime, and lack of educational opportunity. 


These social factors influence the prevalence, severity, and prognosis of mental health problems.  Mental health problems still occur frequently, even in affluent, safe, free environments, but it is important in health care to address the core societal needs as the first, most important, and most powerful rung of care.


These issues are very "political," since changes in poverty and social freedoms, etc. require the involvement of a community's leadership on all levels.

What is the role of the existing community of therapists and other mental health workers to improve quality and timely access to mental health care?

A common pathway nowadays is to employ a type of  "corporate" model to improve efficiency.  In industry, it is very clear that an assembly line is much more efficient, to produce the largest quantity of goods, with good quality control, in a very consistent, standardized way, with the least possible amount of money and time.    Such an approach requires teams of workers, supervised by managers, with each individual worker having a particular area of specialization.

In many corporations or businesses--such as banks--there are also regular efforts to evaluate employee performance, so as to enhance productivity.   There may be performance reviews done by management, or perhaps quotas to meet, or quantified analysis of productivity which is then reviewed regularly. 

The mental health analogy of an assembly line would be a type of corporate structure, with various members of a team involved in care.  So one might deal with a clerical worker to organize appointment times, a social worker, an occupational therapist, a nurse, a primary care physician, a clinical counselor, and a psychiatrist.  Even prior to entering this structure, one could deal with friends, family, peer support volunteers, or in a university setting it could be professors, residence workers, etc.

In order for such a system, with multiple rungs of care involved, to work smoothly and helpfully, there would need to be a sense of warm, harmonious collaboration, allowing the experience of being supported by a community.

The risk of such a system, particularly if it is not running smoothly, is that a person could feel like their care was divided or pigeon-holed.  It could indeed feel like interacting with a corporation, in the negative sense of the word.  (For a particularly critical set of insights about this, I am reminded of the documentary book and film by UBC law professor Joel Bakan, entitled The corporation). 

Performance reviews often could lead to a dramatic reduction in morale in an organization, even if the short-term goal of increased "productivity" is reached.  Generally it is stressful for workers to feel scrutinized in a hierarchical system.  Another consequence of a highly monitored work environment could be subtle changes in the pattern of practice:  workers may avoid more difficult, chronic cases, since these would be more likely to lead to negative "productivity ratings."   Creative initiatives in the workplace could become inhibited, since it would be "safer" from a productivity point of view to stick with established practices.  Also, this type of environment would lead to a type of natural selection process, in which workers with a greater tolerance for such scrutiny and stress would become more abundant in the worker population.  Those workers with less tolerance for this would become less prevalent in this system, due to burnout, and due to such a person not wanting to apply for work in such a system.  

In some parts of the world, psychiatry is reserved only for "medication consultation," thus leading to atrophy of clinical skills among psychiatrists, as well as overuse of medications, all in rushed, highly medicalized brief appointments. 


While I applaud efforts to improve efficiency, I am aware of serious risks.

I see a rise in bureaucratic activities in health care.  I see more people, including talented, warm-hearted clinicians, spending their time in front of computers, attending meetings, doing research, or doing some kind of administrative task, instead of dealing on a personal level with people in need.   More people are hired, while a smaller proportion of workers' time is spent helping people on a personal level. 

Some types of bureaucracy are unavoidable, and necessary for excellence.  For example, in hi-tech manufacturing, we absolutely must cooperate with specialists, many of whom across the world, to share the task of creating something amazing or world-changing.  The creation of a modern computer or airplane requires hundreds of highly specialized steps, starting from the mining and processing of rare earth metals, to metallurgical processing, to specialized manufacturing of countless components, to involvement of mathematicians, physicists, engineers, and other designers.  The finances for such projects need to be organized by people with expertise in commerce and business.

Mental health care does have some aspects in common with airplane manufacturing!    But in many ways I believe that it is quite different.

Most patients I see have not really benefited from bureaucratic involvements, but rather have been stressed by them.   Hi-tech therapeutic "tools" have often been tried, ranging from trials of "manualized" therapy to computer apps, to sophisticated combinations of medications.    

I do not claim that such "tools" are unimportant (actually I think many of them are interesting, clever, imaginative, and uniquely helpful for many),  but rather that they must not become the sole focus of a network of health care,  that is becoming increasingly impersonal, bureaucratized and corporatized.

The foundations of mental health care are personal empowerment, through economic and educational freedom, followed by the opportunity to have a reliable, stable personal relationship with a helping figure if desired.   Physical treatments should be available but not pushed upon people as a default approach, or because personal care was not an option. 

If the system is preoccupied with technical and bureaucratic aspects of care, at the expense of personal relationships, then I believe we are facing a steep decline in the quality and availability of mental health care for those most in need.

A particularly insidious part of this problem would be that an assembly-line type of mental health care bureaucracy could most certainly allow more people to be seen, to shorten wait lists, etc.  This could lead an external observer to assume that the system had improved.   But the decline in quality -- which could risk becoming part of a cultural norm, just as fast-food restaurants or donut shops have become a community norm -- may not be noticed or addressed.  


In order to protect the quality of mental health care, I encourage those who have had a positive experience of their own care to be sure to speak up, to offer feedback and advocacy if possible, so as to guide the system towards providing similar positive care experiences for others.  


Personal care is expensive to society, in terms of time and money.  Bureaucratic care is undoubtedly less expensive, at least in a shorter-term view.   At present, many people in dire need have no care at all.  Arguably, economically efficient bureaucratic care is preferable to no care at all.

But another option is for our society to invest much more attention and time to offer high-quality, personal care for everyone.   For this to occur, or to continue, it is likely that advocacy is needed.

Reference:

Bakan, J. (2004). The corporation: the pathological pursuit of power and profit. New York: Free P.

Thursday, February 4, 2016

CBT Therapists prefer Psychodynamic for themselves

Last summer a professional colleague quoted a research finding, that CBT therapists, if they had to choose a style of therapy for themselves personally, preferred psychodynamic therapy.  I haven't been able to locate the exact source of  this finding-- perhaps it was a survey at a conference. 

Here, by "psychodynamic" I mean an open style of therapy, which is based on empathy, exploration, reflection, consideration of interpersonal patterns, consideration of existential issues, building insight, and particularly on attending to the relationship between therapist and patient or client.  Psychodynamic therapy is much less focused on symptom questionnaires, "psychoeducation,"  prescription of exercises, reviewing worksheets, etc.

During a subsequent discussion I had with a leading CBT specialist, this theme recurred--about how  meaningful and helpful it was for that person to have had a long-term personal experience with psychodynamic therapy.

CBT is a very much more "data-driven" style.  Psychodynamic styles are less so.   While I find CBT approaches extremely important, it is also true that because they are "data-driven" it will be naturally much easier to generate certain types of data from trials of CBT.  There would be a built-in bias favouring CBT in research.  Those therapists who are very inclined towards "data gathering" would likely be much more inclined towards CBT, and in turn would probably be more inclined to spend time publishing in research journals.  Psychodynamic therapists, on average, are simply less interested in publishing research papers. 

Those studies comparing CBT with other styles of therapy sometimes show advantages of CBT -- but many do not.   And most comparative studies are very brief in duration.

The meaningful, positive elements of psychodynamic styles of therapy are likely to require longer periods of time to evaluate.  Such long time periods are more difficult to measure in a study, due to technical limitations.

The inefficiencies of psychodynamic therapies, as manifest in some of the research, have often stemmed from applying old-fashioned psychoanalytic ideas in a dogmatic or highly passive way, and from offering long-term psychodynamic therapies to all patients, without any attention to shorter-term CBT-style work.  A "blended model" could involve attending to CBT ideas with most patients, but also offering longer-term psychodynamic therapies at the same time, according to patient wishes.    This type of blending is already a natural part of the approach of most therapists on both sides of the "CBT vs. psychodynamic spectrum."  The key feature which is required, in any case, is for the therapist to be kind, patient, empathic, engaging, and available.  

Another related factor, emerging in society in general, is that much of CBT is simply psychoeducational.  Ideas about basic psychological self-care tactics are a major part of every formal CBT course or manual.  The thing is, it is becoming much more prevalent now that people are already educated about CBT ideas.

Therefore, to offer only CBT would be, more commonly, to offer educational material that more and more people are already well-versed and experienced in.

I completely support the idea of increasing the availability of CBT, and of fostering education about self care based on these ideas, starting in childhood.  A lot of CBT could be "taught" as a university or high-school style course.  The manuals for them are similar in size to the workbooks for a typical 3 month course.

But the role of psychodynamic styles is likely to become even more important with time, since more people will already have been well-versed in CBT. 

Monday, January 11, 2016

Light therapy for non-seasonal depression

Lam et al. have published a study this month in JAMA Psychiatry  (http://www.ncbi.nlm.nih.gov/pubmed/26580307 ) in which they show that people with non-seasonal major depressive disorder may have improvements in their mood with daily use of a light box alone.  Previously, light boxes have been used mainly in the treatment of seasonal depression or "SAD."

One of the reasons light therapy is attractive is that it is not a medication:  it is far less likely to cause side effect problems, and therefore it could have a much broader appeal, especially among people who are not comfortable using psychotropic medications.  



In the study, there were four groups:
1) 10 000 Lux light box exposure for 30 minutes as soon after waking as possible (the standard regimen of using light therapy), plus a placebo medication.
2) A "sham" or "placebo device" condition of sitting in front of a buzzing box (an inactive ion generator),  plus a placebo medication
3) 20 mg/day of fluoxetine +  placebo device
4) 20 mg/day fluoxetine + 10 000 Lux light box

The treatment duration was 8 weeks. 

 At the end of the study period, there were no significant differences between the fluoxetine+placebo device and the placebo medication+placebo device groups.   We could conclude from this that monotherapy with 20 mg/d of fluoxetine for 8 weeks had no benefit for treating major depression in this cohort! 

The light box+placebo medication group showed much more improvement (about twice as much change from baseline as the placebo-placebo group), with response rates typical for effective antidepressant therapies.   The combination group did best of all, with a response rate of 76% and a "remission rate" of 59%.

So this study supports the use of a light box alone as a viable therapy for depression, even if the depression does not have a seasonal pattern.
 
However, here are a few possibly cynical queries about this study:

1) while people in the study had to be medication-free for 2 weeks before the study commenced, I would suspect that many people in the study had tried other antidepressants.  This was not clearly documented.  By far the most common antidepressants that they would have tried would have been SSRIs.  Obviously, any SSRI trial would not have led to satisfactory improvement in these people, otherwise they wouldn't still be depressed!   In general there is not a lot of evidence that one SSRI is very different from any other, in terms of effectiveness.  Therefore, the study would have been biased against the medication group, in favour of the outcome which I presume the authors desired (which is to show that "light therapy is good").  If the authors wanted to control more powerfully for this factor, it would be necessary for them to assemble a cohort of depressed patients who had no prior history with antidepressants.


2) it is not hard to imagine that bright light could be a healthy, wholesome way to start the day.  It is much harder to imagine that sitting in front of a buzzing dark box could be beneficial.  The study demonstrated that the "expectancy scores" were the same for each of the four groups, i.e. that people in each of the 4 groups had a similar belief that the treatment they were receiving could be beneficial.   Yet, I question how compelling it would be for a modern person to believe that sitting in front of a buzzing box daily for 8 weeks would lead to a positive mood change or health benefit.

Furthermore, the treatments were absolutely not "blinded."  It would be obvious to the person sitting in front of the light box that they were receiving light therapy!  The person sitting in front of the buzzing box would be fully aware of not receiving light therapy!

3) people in the study were apparently told not to "spend an excessive or unusual amount of time outside" during the study!   If you are told not to go outside, do you not think that you might benefit even more from bright light indoors?   What if the effect of time outside exceeds the effect of the light box?!  In this case, how about prescribing that people just go outside for a half-hour in the morning after sunrise?   I'd be curious to see a study comparing a half hour walk outside with a half hour sitting in front of a light. 


Is a commercial 10 000 Lux light box really necessary?   How well can a person tell the difference between light intensities?    In various prior studies, the "sham" light therapy was a dim red light.  Here again, such a "device placebo" is not truly blinded!  Being stuck in front of a dim red light for half an hour sounds depressing just to think about!

The most interesting study I have come across looking at some of these questions was published by Riemersma-van der Lek et al in JAMA in 2008.  http://www.ncbi.nlm.nih.gov/pubmed/18544724
They had different lighting levels in nursing homes, followed for over a year.  People living in the homes could not guess accurately whether they were in the bright light condition or not (the intensities were approximately 1000 Lux vs 300 Lux, all day).  The brighter light seemed to cause some positive effects, and also eliminated negative effects caused by nightly melatonin administration.

To have a truly blinded study, we would need to use a light box of the same size, with the same colour of light, but with a lower intensity (for example, 5 000 Lux), but such that the person exposed to this light would not be able to guess the intensity level correctly.  That is, if you sat in front of the lower intensity light box, you wouldn't be able to tell that you were in the "dim light" group. This is reasonable to expect, since the visual system adjusts remarkably to different lighting conditions, causing wide ranges of measured illumination to be perceived similarly unless they are contrasted directly with each other at the same time. 

It would also be useful to more carefully assess the relationship, if any, between light therapy duration and intensity with clinical symptom changes.  What about 20 minutes vs. 30 minutes?  Or 7 000 Lux vs 10 000 Lux?   I suspect that the 10 000 Lux, 30 minute regimen is more arbitrary than one might expect. 

I have little doubt that bright light first thing in the morning is beneficial for mood--it seems like an obviously wholesome thing, which could also help regulate behaviour and sleep-wake patterns etc.  It could also be an opportunity to structure a type of meditative or study time in the morning.

But is a commercial product really necessary?  A typical "light box" costs about $200.  The electrical components inside are probably worth no more than perhaps $20-40.  It is just a fluorescent light!
It would be reasonable to conduct studies with "home made" light therapy, including just turning on a few extra lamps, or even just sitting in front of a bright east-facing window!  While the 30-minute treatment could be enjoyable and meditative for some, or a time to start the day with a bit of reading, it may be that the sedentary nature of light box exposure could be unhelpful for at least some people.  For these others, perhaps they could use that 30 minute time more healthily to get outside for a walk, instead of sitting in front of a box. 

One of the other applications for a light box that I have recommended to people is to help with morning sleep habits.  Many people have trouble waking and getting up out of bed at a regular hour (this regularity being a cornerstone of healthy sleep habits!).  Using a light box next to the bed, connected to a timer circuit which turns it on at the same hour each morning, could be used to help consolidate a regular sleep routine.  It would be like an "artificial sunrise."  (Of course, a natural sunrise would be much better still, but in our modern indoor world, it is hard to arrange this; also in a northerly latitude, the sun rises very late during the winter months, which is most likely a factor in causing seasonal mood and sleep changes).    So, using bright light as an "alarm clock" could be an idea worth trying, especially in the winter months.